I agree that we need some solid research supporting broad brush company statements that the product is 'clinically superior'...
This research concerns me...
https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0038-1628328
"In contrast to advertisement statements, CardioCel patches demonstrated proliferations in every specimen and calcifications in all 6 specimen with implant times of 23 months or more. However, histology of this patch material showed less optimal results in-short and medium-term explants. Long-term follow-up in larger cohorts is required to determine the definitive patch performance for AV reconstruction".
Ann: Extension of Voluntary Suspension, page-65
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.15 |
Change
0.000(0.00%) |
Mkt cap ! $291.2M | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.15 | $14.60 | $347.8K | 23.20K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 760 | $15.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.15 | 388 | 1 |
View Market Depth
| Last trade - 15.58pm 30/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |